Danaher Corp
DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value
$232.23−4.75 (-2.00%)
Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –
Danaher U.S. Industry Benchmark by Year
U.S. Industry Benchmark — U.S. Industry Total PMA Approvals
Danaher U.S. Industry Benchmark: 2,222 in FY2025, down 0.4% from a year earlier.
Latest, FY2025
2,222
Period ended Dec 31, 2025
Change on a year earlier
-0.4%
2,230 in FY2024
History
11 years
Since FY2015
Sources
1
U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE)
Where the FY2025 figure comes from
Source: U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Reported in U.S. FDA openFDA Device PMA API.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Danaher U.S. Industry Benchmark, annual FY2015–FY2025 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/ext-fda-pma-us-industry
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.